SINGAPORE – Asia has all the building blocks necessary to be at the vanguard of drug innovation, so what is stopping it from being on an equal footing with mature markets such as the U.S. and Europe? Industry experts at the 2017 BioPharma Asia Convention pointed to the need for a change in the region’s mindset toward innovation. Read More
NEW DELHI – India’s business environment will remain highly challenging for innovative pharmaceutical firms, according to BMI Research. The report comes on the heels of the February U.S. Chamber International IP Index, which ranks India very low in intellectual property (IP) – 43rd among 45 countries that represent 90 percent of the global GDP. Read More
A peptide extracted from spider venom was shown in an Australian study to reduce brain damage and improve neurological performance in rats, potentially leading to development of new therapies to protect the brain from stroke and other ischemic brain injuries. Read More
SINGAPORE – Asia’s rapidly developing health care ecosystem should ease market access for pharmaceutical companies and drug access for patients, but communication and transparency remain a key challenge hindering development. Unless all stakeholders in the sector come together, drug costs will remain high, industry experts said at the BioPharma Asia Convention. Read More
HONG KONG – To facilitate the growth of pharmaceutical markets and expedite drug approvals throughout the 10-country Association of Southeast Asian Nations (ASEAN), a consistent regulatory system is needed. Read More
Taigen Biotechnology Co. Ltd. (TGBJ), of Taipei, Taiwan, said its wholly owned subsidiary, Taigen Biopharmaceuticals Co. (Beijing) Ltd., executed an equity purchase agreement to sell its 9 percent equity stake in Dongguan HEC Taigen Biopharmaceuticals Co. Ltd., a joint venture between TGBJ and HEC, to Yichang HEC Changjiang Pharmaceutical Co. Ltd., of Dongguan, China. Under the terms, TGBJ will receive $20 million for the 9 percent equity payable on or before March 31. Read More
